Immunotherapy with Anti-GD2 Antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN Trial Improves Outcome of High-Risk Neuroblastoma Patients Compared to Historical Controls

被引：0
|
作者：
Ladenstein, R. [1 ,2 ,3 ]
Poetschger, U. [1 ]
Valteau-Couanet, D. [4 ]
Gray, J. [5 ,6 ]
Luksch, R. [7 ]
Castel, V. [8 ]
Ash, S. [9 ]
Laureys, G. [10 ]
Owens, C. [11 ]
Trahair, T. [12 ]
Chan, G. C. F. [13 ]
Ruud, E. [14 ]
Schroeder, H. [15 ]
Beck-Popovic, M. [16 ]
Loibner, H. [17 ]
Schreier, G. [18 ]
Ambros, P. [19 ]
Sarnacki, S. [20 ]
Boterberg, T. [10 ]
Lode, H. [21 ]
机构：
[1] St Anna Kinderkrebsforsch eV, Studies & Stat Integrated Res & Projects S2IRP, Vienna, Austria
[2] St Anna Childrens Hosp, Vienna, Austria
[3] Med Univ, Dept Paediat, Vienna, Austria
[4] Gustave Roussy, Children & Adolescent Oncol Dept, Paris, France
[5] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England
[6] Univ Southampton, Paediat Oncol & Haematol, Southampton, Hants, England
[7] Fdn IRCCS Ist Nazl Tumori, Paediat Oncol & Haematol, Milan, Italy
[8] Hosp Univ & Politecn La Fe, Paediat Oncol & Haematol, Valencia, Spain
[9] Tel Aviv Univ, Schneider Childrens Med Ctr Israel, Sackler Fac Med, Paediat Oncol & Haematol, Petah Tiqwa, Israel
[10] Univ Hosp Ghent, Paediat Oncol & Haematol, Ghent, Belgium
[11] Our Ladys Childrens Hosp, Paediat Haematol Oncol, Crumlin Dublin, Ireland
[12] Sydney Childrens Hosp, Paediat Oncol & Haematol, Randwick, NSW, Australia
[13] Queen Mary Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China
[14] Natl Hosp Norway, Paediat Oncol & Haematol, Oslo, Norway
[15] Univ Hosp Aarhus, Paediat Oncol Haematol, Aarhus, Denmark
[16] Univ Hosp Lausanne, Paediat Oncol Haematol, Lausanne, Switzerland
[17] Apeiron Biol AG, Vienna, Austria
[18] AIT Austrian Inst Technol GmbH, Ctr Hlth & Bioresources, Graz, Austria
[19] St Anna Kinderkrebsforsch eV, Tumour Biol, Vienna, Austria
[20] Paris Descartes Univ, Necker Enfants Malad Hosp, Dept Pediat Surg, Paris, France
[21] Univ Med Greifswald, Paediat Oncol & Haematol, Greifswald, Germany
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-097
引用
收藏
页码：S53 / S54
页数：2
相关论文
共 49 条
  • [1] Immunotherapy with anti-GD2 antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.
    Ladenstein, Ruth Lydia
    Poetschger, Ulrike
    Couanet, Dominique Valteau
    Gray, Juliet
    Luksch, Roberto
    Castel, Victoria
    Ash, Shifra
    Laureys, Genevieve
    Owens, Cormac
    Trahair, Toby
    Chan, Godfrey Chi Fung
    Ruud, Ellen
    Schroeder, Henrik
    Popovic, Maja Beck
    Loibner, Hans
    Schreier, Guenter
    Ambros, Peter F.
    Sarnacki, Sabine
    Boterberg, Tom
    Lode, Holger N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
    Ladenstein, Ruth
    Poetschger, Ulrike
    Valteau-Couanet, Dominique
    Luksch, Roberto
    Castel, Victoria
    Yaniv, Isaac
    Laureys, Genevieve
    Brock, Penelope
    Michon, Jean Marie
    Owens, Cormac
    Trahair, Toby
    Chan, Godfrey Chi Fung
    Ruud, Ellen
    Schroeder, Henrik
    Popovic, Maja Beck
    Schreier, Guenter
    Loibner, Hans
    Ambros, Peter
    Holmes, Keith
    Castellani, Maria Rita
    Gaze, Mark N.
    Garaventa, Alberto
    Pearson, Andrew D. J.
    Lode, Holger N.
    LANCET ONCOLOGY, 2018, 19 (12): : 1617 - 1629
  • [3] Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial).
    Ladenstein, Ruth
    Poetschger, Ulrike
    Gray, Juliet
    Valteau-Couanet, Dominique
    Luksch, Roberto
    Castel, Victoria
    Yaniv, Isaac
    Laureys, Genevieve
    Elliott, Martin
    Michon, Jean Marie
    Owens, Cormac
    Trahair, Toby
    Chan, Godfrey Chi Fung
    Ruud, Ellen
    Schroeder, Henrik
    Popovic, Maja Beck
    Glogova, Evgenia
    Schreier, Guenter
    Loibner, Hans
    Lode, Holger N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] The Influence of Surgical Excision on Survival in High-Risk Neuroblastoma Revisited After Introduction of ch14.18/CHO Immunotherapy in the HR-NBL1/SIOPEN Trial
    Ladenstein, R.
    Poetschger, U.
    Sarnacki, S.
    Monclair, T.
    Cecchetto, G.
    Gomez-Chacon, J.
    Stenman, J.
    Joseph, J. M.
    Luksch, R.
    Castel, V.
    Ash, S.
    Papadakis, V.
    Malis, J.
    Balwierz, W.
    Owens, C.
    Lode, H.
    Boterberg, T.
    Valteau-Couanet, D.
    Pearson, A. D.
    Holmes, K.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S36 - S37
  • [5] The role of anti-GD2 CH14.18/CHO monoclonal anti-body based immunotherapy within the HR-NBL1/SIOPEN trial. comparison of two treatment ERAS
    Ladenstein, Ruth
    Poetschger, Ulrike
    Valteau-Couanet, Dominique
    Luksch, Roberto
    Castel, Victoria
    Ash, Shifra
    Laureys, Genevieve
    Brock, Penelope
    Michon, Jean Marie
    Owens, Cormac
    Trahair, Toby
    Chan, Godfrey Chi Fung
    Ruud, Ellen
    Schroeder, Henrik
    Popovic, Maja Beck
    Schreier, Guenter
    Loibner, Hans
    Ambros, Peter
    Holmes, Keith
    Castellani, Maria Rita
    Gaze, Mark N.
    Garaventa, Alberto
    Pearson, Andrew D. J.
    Lode, Holger N.
    BONE MARROW TRANSPLANTATION, 2019, 54 : 125 - 125
  • [6] The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/CHO immunotherapy in the HR-NBL1/SIOPEN trial.
    Holmes, Keith
    Poetschger, Ulrike
    Sarnacki, Sabine
    Monclair, Tom
    Cecchetto, Giovanni
    Chacon, Javier Gomez
    Stenman, Jacob
    Joseph, Jean-Marc
    Luksch, Roberto
    Castel, Victoria
    Ash, Shifra
    Papadakis, Vassilios
    Malis, Josef
    Balwierz, Walentyna
    Owens, Cormac
    Lode, Holger N.
    Boterberg, Tom
    Couanet, Dominique Valteau
    Pearson, Andrew D. J.
    Ladenstein, Ruth Lydia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] MYELOABLATIVE THERAPY (MAT) AND IMMUNOTHERAPY (IT) WITH CH14.18/CHO FOR HIGH RISK NEUROBLASTOMA: UPDATE AND NEWS OF RANDOMISED RESULTS FROM THE HR-NBL1/SIOPEN TRIAL
    Ladenstein, R.
    Poetschger, U.
    Luksch, R.
    Elliot, M.
    Castel, V.
    Yaniv, I.
    Laureys, G.
    Balwierz, W.
    Lode, H. N.
    Valteau-Couanet, D.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S122 - S123
  • [8] Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody
    Siebert, Nikolai
    Seidel, Diana
    Eger, Christin
    Juettner, Madlen
    Lode, Holger N.
    PLOS ONE, 2014, 9 (09):
  • [9] Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma
    Ami V. Desai
    Elizabeth Fox
    L. Mary Smith
    Allison Pecha Lim
    John M. Maris
    Frank M. Balis
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1047 - 1055
  • [10] Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma
    Desai, Ami V.
    Fox, Elizabeth
    Smith, L. Mary
    Lim, Allison Pecha
    Maris, John M.
    Balis, Frank M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1047 - 1055
12345